Clinical Trials Logo
  1. Home
  2. Herpes Simplex
  3. NCT04762511

A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years

Herpes Simplex Clinical Trial

Official title:
A Phase I, Single-blind, Randomised, Placebo-controlled, Dose Escalation Study to Evaluate the Reactogenicity, Safety and Immune Response of an HSV Vaccine in Healthy Participants Aged 18-40 Years

Clinical Trial Summary

The purpose of this first-time-in-human (FTiH) study is to assess the reactogenicity, safety and immunogenicity of four different dose levels of an experimental herpes simplex virus type 2 (HSV-2) vaccine, when administered intramuscularly (IM) on a 0, 2-month schedule to healthy participants aged 18-40 years.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04762511
Study type Interventional
Source GlaxoSmithKline
Contact
Status Terminated
Phase Phase 1
Start date March 2, 2021
Completion date May 26, 2021
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05468619 - Neonatal Phase 1 Valacyclovir Study Phase 1
Withdrawn NCT02349828 - Antiviral Prophylaxis in a Burn Population Phase 2/Phase 3
Recruiting NCT01176409 - Can Valacyclovir Attenuate Inflammation in Antiretroviral-Treated HIV-Infected Individuals With Herpes Simplex Virus Type 2? Phase 3
Completed NCT04664127 - Study of the Efficacy and Safety of Combined Treatment of Patients With Severe Herpes Simplex (HSV) Infection by Valacyclovir and Interferon Inducer Kagocel
Completed NCT00448227 - Pharmacokinetics, Acceptability and Safety of Famciclovir in Infants (1 Month to Less Than 12 Months) With Herpes Simplex Infection Phase 2
Completed NCT00000139 - Herpetic Eye Disease Study (HEDS) II Phase 3
Completed NCT04239521 - The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
Completed NCT02209324 - Open-label Study of ASP2151 in Herpes Simplex Patients Phase 3
Completed NCT00855309 - Acyclovir in Preventing Herpes Simplex Virus Infection in Patients With Neutropenia Phase 3
Completed NCT01602562 - Valaciclovir Hydrochloride Phase III for Hematopoietic Stem Cell Transplantation Patients Phase 3
Completed NCT00973466 - Prevalence of Sexually Transmitted Infections (STIs) in HIV-infected Patients N/A
Completed NCT00698893 - Evaluation of Safety of Candidate gD Vaccine, With or Without MPL in Healthy Herpes Simplex Virus-positive Adults Phase 1
Active, not recruiting NCT05298254 - A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes Phase 1/Phase 2
Recruiting NCT03178747 - Tzanck Smear With Methylene Blue Stain for Herpes Phase 3
Completed NCT00164424 - Episodic Acyclovir Therapy for Genital Ulcers Phase 2/Phase 3
Completed NCT00161434 - A Study of Valacyclovir to Suppress HSV and HIV Shedding in Coinfected Persons Phase 4
Completed NCT00699764 - Safety of a Herpes Simplex Candidate Vaccine (gD2t) With MPL and Its Efficacy to Prevent Genital Herpes Disease Phase 3
Recruiting NCT04065971 - Randomized, Placebo-controlled, Double-blind Study of 2LHERP® in Orofacial Herpes Infections. Phase 4
Active, not recruiting NCT00005663 - A Study of Valacyclovir as Treatment for Genital Herpes Simplex Virus in HIV-Infected Patients Phase 3
Recruiting NCT00006132 - Phase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Involving the Central Nervous System Phase 3